Trial Profile
A Phase 1b/Randomized Phase 2 Study to Evaluate LY3039478 in Combination with Dexamethasone in T-ALL/T-LBL Patients
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 12 Dec 2022
Price :
$35
*
At a glance
- Drugs Crenigacestat (Primary) ; Dexamethasone
- Indications Precursor T-cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Eli Lilly and Company (India) Pvt. Ltd
- 27 Oct 2020 Results of phase 1 part of the study published in the Cancer
- 09 Jul 2018 Status changed from active, no longer recruiting to completed.
- 24 Jan 2018 Planned End Date changed from 1 Mar 2018 to 1 Jan 2018.